Insider Buying: BioCardia, Inc. (NASDAQ:BCDA) Director Buys $52,331.90 in Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon H. Stertzer purchased 22,753 shares of BioCardia stock in a transaction dated Monday, March 3rd. The stock was bought at an average price of $2.30 per share, with a total value of $52,331.90. Following the completion of the transaction, the director now owns 40,602 shares of the company’s stock, valued at $93,384.60. This represents a 127.47 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

BioCardia Price Performance

BCDA opened at $2.62 on Friday. The firm has a market capitalization of $12.01 million, a P/E ratio of -0.63 and a beta of 1.28. BioCardia, Inc. has a one year low of $1.63 and a one year high of $6.90. The company has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.44.

Analysts Set New Price Targets

A number of research analysts have weighed in on BCDA shares. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Wednesday, December 18th.

Hedge Funds Weigh In On BioCardia

An institutional investor recently raised its position in BioCardia stock. Geode Capital Management LLC lifted its holdings in shares of BioCardia, Inc. (NASDAQ:BCDA) by 110.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,987 shares of the company’s stock after purchasing an additional 16,251 shares during the quarter. Geode Capital Management LLC owned 0.68% of BioCardia worth $68,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.